TORONTO--(BUSINESS WIRE)--Medworxx Solutions Inc. ("Medworxx") (TSX VENTURE: MWX) today announced a non-exclusive agreement with EY – formerly Ernst & Young - to leverage each organisation’s expertise in Process Redesign Optimisation. The Medworxx Clinical Utilisation Review (CUR) program is widely accepted by hospitals and health systems internationally. The CUR methodology leverages the Medworxx Clinical Criteria Module software to unlock unique patient flow information to help organisations understand the scope of their patient flow issues and identify specific opportunities to improve quality and performance.
In the United Kingdom (UK), the introduction of the NHS England CQUIN 2015/2016 schedules presents a highly specialized opportunity for both Medworxx and EY. The CQUIN demonstrates the NHS’ commitment to Clinical Utilisation Review as an essential tool to affect patient flow improvement by providing NHS Hospital Trusts with risk-free set-up funding and ongoing financial support and incentives to develop and embed robust Clinical Utilisation Review systems. EY will work with Medworxx to introduce and implement the Medworxx CUR solution to the NHS organisations.
“The CQUIN represents a great opportunity for CUR to be adopted rapidly in the UK. As a leading Process and Redesign advisory service, EY is positioned to help organisations realize their optimal potential. After reviewing Medworxx results we strongly believe the combination of expertise from both organisations will create a compelling overall solution,” said, Joe Stringer, Partner, EY Healthcare Advisory, UK.
“Establishing partnerships with consulting companies is an important component in our go to market strategy internationally,” said Dan Matlow, President and Chief Executive Officer, Medworxx. “Having a global partner like EY is validation of the value of our data.”
EY is a global leader in assurance, tax, transaction and advisory services. The insights and quality services we deliver help build trust and confidence in the capital markets and in economies the world over. We develop outstanding leaders who team to deliver on our promises to all of our stakeholders. In so doing, we play a critical role in building a better working world for our people, for our clients and for our communities.
EY refers to the global organisation and may refer to one or more of the member firms of Ernst & Young Global Limited, each of which is a separate legal entity. Ernst & Young Global Limited, a UK company limited by guarantee, does not provide services to clients. For more information about our organisation, please visit http://www.ey.com .
Medworxx delivers health information solutions to over 350 hospitals internationally; including Canada, United States and United Kingdom. Medworxx helps hospitals meet patient flow challenges, and requirements in compliance and education. Medworxx Clinical Criteria – flagship of Medworxx Patient Flow that includes electronic bed board and independent assessment components – currently serves 32% of the acute care beds in Canada. Founded in 2004, Medworxx is based in Toronto, ON, and publicly traded on the TSX Venture Exchange: MWX. For more information visit: http://www.medworxx.com.
The statements made in this press release may contain forward-looking statements that may involve a number of risks and uncertainties. Actual events or results could differ materially from the company’s expectations and projections. The TSX Venture Exchange has not reviewed this press release and neither approved nor disapproved the information contained in this press release.